Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: Half-year report of the liquidity contract with
the stockbroker company Gilbert Dupont
02-Jul-2020 / 13:59 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
Aubagne, France, July 2, 2020
Half-year report of the liquidity contract with the stockbroker company
Gilbert Dupont
Under the liquidity contract concluded between SARTORIUS STEDIM BIOTECH and
the stockbroker Gilbert Dupont, the following assets appeared on the
liquidity account on June 30, 2020:
· Number of shares: 1,941
· Liquidity account cash balance: EUR 591,334.56
During the first half of 2020, the following were negotiated:
ORDER INTAKE 23,591 EUR 4,975,493.7 972 transactions
securities 5
SALES 24,875 EUR 5,196,135.5 1,037
securities 9 transactions
It should be noted that in the second half of 2019, which ended December 31,
2019, the following assets appeared on the liquidity account:
· Number of shares: 3,225
· Liquidity account cash balance: EUR 370,692.66
It should also be noted that upon implementing the liquidity contract, the
following assets were made available:
· Number of shares: 654
· Liquidity account cash balance: EUR 394,895.12
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the
biopharmaceutical industry. As a total solutions provider, the company helps
its customers to manufacture biotech medications safely, rapidly and
economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is
quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D
sites in Europe, North America and Asia and an international network of
sales companies, Sartorius Stedim Biotech has a global reach. The Group has
been annually growing by double digits on average and has been regularly
expanding its portfolio by acquisitions of complementary technologies. In
2019, the company employed approx. 6,200 people, and earned sales revenue of
EUR 1,440.6 million.
Contact
Ben Orzelek
Head of Investor Relations
+49 (0)551.308.1668
Ben.orzelek@sartorius.com
Sartorius Stedim Biotech S.A.
Z.I. Les Paluds
Avenue de Jouques, CS 91051
13781 Aubagne Cedex, France
Phone: +33.(0)4.42.84.56.00
Fax: +33.(0)4.42.84.56.19
www.sartorius-stedim.com
Regulatory filing PDF file
File: Half-year report of the liquidity contract with the stockbroker
company Gilbert Dupont [1]
Language: English
Company: Sartorius Stedim Biotech SA
Avenue de Jouques
13781 Aubagne
France
Phone: +33 44 284 5600
E-mail: info@sartorius-stedim.com
Internet: www.sartorius-stedim.com
ISIN: FR0013154002
Euronext Ticker: DIM
AMF Category: Share buyback / Disposal of own shares / Information
relating to the liquidity contract
EQS News ID: 1084849
End of Announcement EQS News Service
1084849 02-Jul-2020 CET/CEST
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=21150fc8c7080a10a9b2093f216307d1&application_id=1084849&site_id=vwd&application_name=news
(END) Dow Jones Newswires
July 02, 2020 07:59 ET (11:59 GMT)
